Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
NCT07481799Phase 3Recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug vedotin in solid tumor. Started Feb 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07481799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481799.